Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

Phase: N/A Priority: Normal
NCT ID: NCT02106091 Org: User:
Start: 04/30/14 End: 09/30/18 Due: 09/30/19

Study to Assess AFM24 in Advanced Solid Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04259450 Org: User:
Start: 04/07/20 End: 06/24/24 Due: 06/24/25

A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01221571 Org: User:
Start: 10/31/10 End: 06/30/13 Due: 06/30/14

First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05817058 Org: User:
Start: 03/21/23 End: 03/31/26 Due: 03/31/27

Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL

Phase: N/A Priority: Normal
NCT ID: NCT02848911 Org: User:
Start: 10/31/16 End: 04/30/19 Due: 04/30/20

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02665650 Org: User:
Start: 05/31/16 End: 03/31/19 Due: 03/31/20

Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05109442 Org: User:
Start: 11/19/21 End: 11/30/25 Due: 11/30/26

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Phase: N/A Priority: Normal
NCT ID: NCT04101331 Org: User:
Start: 11/13/19 End: 01/11/24 Due: 01/11/25

Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

Phase: N/A Priority: Normal
NCT ID: NCT05883449 Org: User:
Start: 10/10/23 End: 11/30/27 Due: 11/30/28